AB0517 CORRELATION BETWEEN PATIENT-REPORTED OUTCOMES OF HEALTH-RELATED QUALITY OF LIFE AND CLINICAL ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
Authors: Elena Grau García, Jorge Juan Fragio-Gil, Roxana Gonzalez Mazario, Carmen Nájera Herranz, Inés Cánovas Olmos, Jose Ivorra Cortés, Cristina Alcañiz Escandell, Inmaculada Chalmeta Verdejo, Marta De la Rubia Navarro, Luis Gonzalez Puig, Isabel Martínez Cordellat, Rosa Negueroles Albuixech, Jose Eloy Oller Rodríguez, Francisco Miguel Ortiz Sanjuan, Cristobal Pávez Perales, Elvira Vicens Bernabeu, David Hervás Marín, Jose Andrés Román Ivorra
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Patient-Reported Outcomes (PROs) allow us to know the way the disease could affect patients, and maybe could not be detected in clinical measures. Among these, PROs of health-related quality of life (PRO-QL) represents patient evaluation of its health status and treatment, which affects the functional, psychological, social and emotional capabilities. In fact, patients with the same health status could show different PROs-QL. In the case of systemic lupus erythematoSus (SLE), patients experience many inflammatory symptoms and all of them can affect the health-related quality of life in different ways. <h3>Objectives:</h3> We aimed to measure the PRO-QL in SLE patients and correlate them with the clinical activity of the disease. <h3>Methods:</h3> A cross-sectional observational study with SLE patients diagnosed according to SLICC 2012 criteria was performed. In all cases SLEDAI score was carried out, and patients full-filled questionnaires of fatigue (FACIT-FATIGUE), quality of life (EQ-5D-5L), disability (HAQ) and a Global Health Status Scale (GHS) (0-100). Biostatistical analysis with software R was performed, using the multivariate analysis of variance by Pillai test. <h3>Results:</h3> 54 SLE patients (91.84% female) participated in the study, with a mean age at diagnosis of 27.55±13.21 years <i>and a mean time of disease evolution</i> of 20.45±9.7 years. Mean SLEDAI score was 6.63±6.89, with a 37.04% of patients with SLEDAI&gt;6. The 64.66% of patients were under glucocorticoid treatment, 38.77% under immunosupressants (methotrexate, azatioprine o mycophenolate) and 51.02% under antimalarials. Patients showed a mean score of 34.02±12.38 in FACIT-FATIGUE, 0.72±0.26 in EQ-5D-5L, 0.62±0.71 in HAQ and 64.02±25.93 in GHS. Statistical analysis showed correlation between SLEDAI score and the four questionnaires of PROs-QL (P&lt;0.001). Particularly in those cases with high clinical activity we observed low scores of EQ-5D-5L, FACIT-FATIGUE and GHS, and an increment in HAQ. We performed the previous analysis considering as correcting factors the age, years of disease evolution, glucocorticoid treatment, antimalarials and inmunosupressants. We also obtained a correlation between clinical activity and PROs-QL (P=0.0107). <h3>Conclusion:</h3> We observed a correlation between PROs-QL full-filled by SLE patients with the clinical activity of the disease, independently of glucocorticoid treatment, antimalarials and inmunosupressants, the age and the disease evolution. <h3>Disclosure of Interests:</h3> None declared